Trillium Therapeutics (NASDAQ:TRIL) jumps 50% premarket on average volume in concert with Forty Seven (+62%) on the heels of Gilead’s $4.9B bid for the latter.
FTSV’s lead candidate is anti-CD47 monoclonal antibody magrolimab, in development for acute myeloid leukemia and myelodysplastic syndromes.
TRIL’s lead drug is TTI-621, also a CD47 inhibitor, in development for solid tumors and mycosis fungoides (type of cutaneous T cell lymphoma).
https://seekingalpha.com/news/3547358-trillium-up-50-premarket-on-gilead-takeout-of-forty-seven
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.